izpis_h1_title_alt

Selective DNA gyrase inhibitors : multi-target in silico profiling with 3D-pharmacophores
ID Tomašič, Tihomir (Author), ID Zubrienė, Asta (Author), ID Skok, Žiga (Author), ID Martini, Riccardo (Author), ID Pajk, Stane (Author), ID Sosič, Izidor (Author), ID Ilaš, Janez (Author), ID Matulis, Daumantas (Author), ID Bryant, Sharon D. (Author)

.pdfPDF - Presentation file, Download (6,96 MB)
MD5: 42D4C98F97AD2A18F3261BF6EAA8618E
URLURL - Source URL, Visit https://www.mdpi.com/1424-8247/14/8/789 This link opens in a new window

Abstract
DNA gyrase is an important target for the development of novel antibiotics. Although ATP-competitive DNA gyrase (GyrB) inhibitors are a well-studied class of antibacterial agents, there is currently no representative used in therapy, largely due to unwanted off-target activities. Selectivity of GyrB inhibitors against closely related human ATP-binding enzymes should be evaluated early in development to avoid off-target binding to homologous binding domains. To address this challenge, we developed selective 3D-pharmacophore models for GyrB, human topoisomerase IIα (TopoII), and the Hsp90 N-terminal domain (NTD) to be used in in silico activity profiling paradigms to identify molecules selective for GyrB over TopoII and Hsp90, as starting points for hit expansion and lead optimization. The models were used to profile highly active GyrB, TopoII, and Hsp90 inhibitors. Selected compounds were tested in in vitro assays. GyrB inhibitors 1 and 2 were inactive against TopoII and Hsp90, while 3 and 4, potent Hsp90 inhibitors, displayed no inhibition of GyrB and TopoII, and TopoII inhibitors 5 and 6 were inactive at GyrB and Hsp90. The results provide a proof of concept for the use of target activity profiling methods to identify selective starting points for hit and lead identification.

Language:English
Keywords:antibacterial, ATP-competitive, DNA gyrase, Hsp90, pharmacophore model, topoisomerase II, target activity profiling, topoisomerase IIα
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:24 str.
Numbering:Vol. 14, iss. 8, art. 789
PID:20.500.12556/RUL-135975 This link opens in a new window
UDC:546.96:547.8
ISSN on article:1424-8247
DOI:10.3390/ph14080789 This link opens in a new window
COBISS.SI-ID:73095939 This link opens in a new window
Publication date in RUL:05.04.2022
Views:634
Downloads:98
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmaceuticals
Shortened title:Pharmaceuticals
Publisher:MDPI
ISSN:1424-8247
COBISS.SI-ID:517582617 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:10.08.2021

Secondary language

Language:Slovenian
Keywords:protibakterijsko delovanje, farmakoforni model, topoizomeraza IIα, tarčna aktivnost, zaviralci, farmacevtska kemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J1-1717
Name:Razvoj novih zaviralcev Hsp90 s protitumornim delovanjem

Funder:ARRS - Slovenian Research Agency
Project number:BI-LT/20-22-009

Funder:Other - Other funder or multiple funders
Funding programme:COST
Project number:CA15135

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back